Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery

Next Previous
Trial Profile

First-In-Human Study of AK1320 Encapsulated Microspheres (AK1320 MS) In Subjects With Degenerative Spondylolisthesis and Concomitant Symptomatic Spinal Stenosis Who Are Undergoing Decompression And Single Level Instrumented Posterolateral Lumbar Autograft Fusion Surgery

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AK 1320 MS (Primary)
  • Indications Spinal stenosis; Spondylolisthesis
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ENHANCE
  • Sponsors Asahi Kasei Pharma Corp

Most Recent Events

  • 03 Mar 2024 Status changed from active, no longer recruiting to discontinued.
  • 31 Jan 2023 Planned End Date changed from 1 Apr 2024 to 1 Dec 2024.
  • 31 Jan 2023 Planned primary completion date changed from 1 Apr 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top